216 related articles for article (PubMed ID: 26710351)
1. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.
Franchini M; Capuzzo E; Liumbruno GM
Blood Transfus; 2016 Sep; 14(5):413-8. PubMed ID: 26710351
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
3. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
4. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
5. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
Lee WP; Datta BN; Ong BB; Rees A; Halcox J
Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
[TBL] [Abstract][Full Text] [Related]
7. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
[TBL] [Abstract][Full Text] [Related]
8. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
9. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
Moriarty PM; Gray JV; Gorby LK
J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
[TBL] [Abstract][Full Text] [Related]
14. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).
Waldmann E; Parhofer KG
Pathology; 2019 Feb; 51(2):227-232. PubMed ID: 30611543
[TBL] [Abstract][Full Text] [Related]
15. [LDL apheresis: an update and overview. LDL apheresis in Sardinia, Italy (SMILDLa)].
Stefanutti C; Di Giacomo S; Morozzi C
G Ital Nefrol; 2012; 29 Suppl 54():S14-8. PubMed ID: 22388823
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a).
Safarova MS; Moriarty PM
Curr Atheroscler Rep; 2023 Jul; 25(7):391-404. PubMed ID: 37273067
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
Saeed A; Virani SS
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of LDL apheresis in the treatment of cardiovascular disease.
Thompsen J; Thompson PD
Atherosclerosis; 2006 Nov; 189(1):31-8. PubMed ID: 16546196
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) apheresis.
Pokrovsky SN; Afanasieva OI; Ezhov MV
Curr Opin Lipidol; 2016 Aug; 27(4):351-8. PubMed ID: 27213629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
